Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2014

View Archived Issues

Sentitive LSPR-based biosensor rapidly detects cancer biomarkers in serum

Genetically engineered epothilone analogue shows promising efficacy in metastatic breast cancer

CLOCK gene polymorphisms found to be associated with recurrent spontaneous abortions

Mutations in the YY1 gene are linked to intellectual disability

AstraZeneca and Cancer Genetics collaborate on cancer in Central America and the Caribbean

Seres Health closes financing and establishes research collaboration with Mayo Clinic

RPC-1063 meets primary endpoint in phase II study

Inovio's INO-3112 enters phase I/IIa trial in head and neck cancer

Batu Biologics outlines development plans for ValloVax

British investigators describe novel kinase inhibitors for inflammatory diseases

Boehringer Ingelheim's afatinib obtains FDA orphan drug status

Mei Pharma reports data from phase II study of pracinostat in AML

Feasible imaging of joint inflammation with novel radiolabeled anti-FAP antibody

Rosetta Genomics to work with Moffitt Cancer Center on thyroid neoplasia assay

U.S. investigators disclose novel compounds for lysosomal storage diseases

New patent describes novel agents for bacterial and fungal infections

Array BioPharma patents detail novel Trk-A inhibitors

Tonix Pharmaceuticals receives IND clearance for TNX-102 in PTSD

NovaDigm Therapeutics acquires rights to three Candida vaccine antigens

European orphan drug designation awarded to Betalutin for follicular lymphoma

Researchers report data on MAb targeting glypican-3 for HCC

FDA extends review date of NB-32 NDA

Data and safety monitoring board recommends continuation of phase III study of CPX-351

Celsion to acquire EGEN in June 2014

Allergan rejects revised Valeant proposal

Takelda launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...